Sign up
Pharma Capital

Berenberg double-downgrades Spire Healthcare on recovery fears

The German bank's analysts said that Spire's recent profit warning means there is less certainty of a near-term improvement
Spire runs private hospitals
Shares in Spire hit an all-time low following an August profit warning

German bank Berenberg has double-downgraded its recommendation on Spire Healthcare Group PLC to ‘sell’ from ‘buy' due to concerns over its cost base and the likelihood of a turnaround in its fortunes over the short-term.

Berenberg also slashed Spire’s target price to 120p from 290p.

READ: Spire Healthcare shares dive on profit warning, lower NHS referrals

Earlier this week, shares in the FTSE 250-listed firm hit an all-time low after the company warned it expected to report “materially lower” 2018 profits due to lower referrals from Britain’s National Health Service (NHS).

“Monday’s profit warning means we now have even less certainty of a near-term improvement in Spire’s fortunes. Given that guidance was reiterated 10 weeks ago, operations have clearly taken a marked turn for the worse, and the lack of new guidance indicates that management is currently unable to forecast its own business,” analysts at Berenberg said in a note to clients.

Shares in Spire were down 6.3% at 177.50p in mid-morning trade.

Register here to be notified of future SPI Company articles
View full SPI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.